Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Down 31.6% in June

Candel Therapeutics, Inc. (NASDAQ:CADL) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,060,000 shares, a decline of 31.6% from the May 31st total of 1,550,000 shares. Currently, 5.6% of the company’s shares are sold short. Based on an average trading volume of 5,620,000 shares, the short-interest ratio is currently 0.2 days.

Candel Therapeutics Stock Up 5.3 %

NASDAQ CADL traded up $0.31 on Friday, reaching $6.20. The company had a trading volume of 3,588,472 shares, compared to its average volume of 482,306. The company’s fifty day moving average is $8.22 and its 200-day moving average is $4.17. The firm has a market capitalization of $184.51 million, a price-to-earnings ratio of -4.84 and a beta of -0.84. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.00 and a current ratio of 2.00. Candel Therapeutics has a 1-year low of $0.66 and a 1-year high of $14.30.

Candel Therapeutics (NASDAQ:CADL) last released its earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter. On average, research analysts forecast that Candel Therapeutics will post -0.91 earnings per share for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.